ArticleCureus2025
Euglycemic Diabetic Ketoacidosis With Sepsis and Acute Kidney Injury in Critically Ill Patients: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SGLT2 Inhibitors: From Structure-Effect Relationship to Pharmacological Response.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic ketoacidosis (DKA) typically presents with hyperglycemia, but euglycemic diabetic ketoacidosis (EDKA) occurs when patients present with acidosis and normal blood glucose levels. This condition has garnered attention due to its association with sodium-glucose cotransporter-2 (SGLT2) inhibitors and other factors such as sepsis. Acute kidney injury (AKI) often complicates sepsis cases and is associated with metabolic acidosis. Distinguishing between AKI and EDKA can be difficult, particularly when both conditions co-occur, as observed in three ICU cases of sepsis with AKI and EDKA. In this report, the clinical challenges of diagnosing EDKA in critically ill patients, especially in the presence of metabolic acidosis and an elevated anion gap, are highlighted. In these cases, metabolic acidosis was initially attributed to AKI; however, blood ketone levels were essential for confirming EDKA. Treatment for EDKA was prioritized over kidney replacement therapy (KRT), which was only initiated when needed for AKI management. Despite its potential benefits in managing AKI, KRT's role in EDKA treatment requires further investigation. This report emphasizes the importance of early diagnosis of EDKA in diabetic patients with sepsis and AKI, stressing the need for prompt ketone testing and insulin therapy, while acknowledging the ongoing uncertainties surrounding the impact of KRT on prognosis in EDKA cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.